Evidence map›Paper›PMID 31027071›Full record

ArticleMedicine2019

Partial response after treatment with Conversion chemotherapy: A case report of a patient with colon cancer and unresectable hepatic metastases.

Zhaoting Bu, Cheng Lu, Xu Yang, Hao Lai, Yuting Jiang, Yicheng Li, Yuan Lin, Yuzhou Qin, Minxi Xiao, Chunfeng Cheng and 1 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in Medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Zhaoting BuAffiliated Tumor Hospital of Guangxi Medical University.
Cheng LuAffiliated Tumor Hospital of Guangxi Medical University.
Xu YangAffiliated Tumor Hospital of Guangxi Medical University.
Hao LaiDepartment of Gastrointestinal Surgery and Guangxi Clinical Research Center for Colorectal Cancer, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi Autonomous Region, China.
Yuting JiangAffiliated Tumor Hospital of Guangxi Medical University.
Yicheng LiAffiliated Tumor Hospital of Guangxi Medical University.
Yuan LinDepartment of Gastrointestinal Surgery and Guangxi Clinical Research Center for Colorectal Cancer, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi Autonomous Region, China.
Yuzhou QinDepartment of Gastrointestinal Surgery and Guangxi Clinical Research Center for Colorectal Cancer, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi Autonomous Region, China.
Minxi XiaoAffiliated Tumor Hospital of Guangxi Medical University.
Chunfeng ChengAffiliated Tumor Hospital of Guangxi Medical University.
Qi LiuAffiliated Tumor Hospital of Guangxi Medical University.
Tumor Hospital of Guangxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

rationaleMany studies have reported radical resection for liver metastasis and the primary tumor could represent an important prognostic factor in patients affected by colorectal liver metastases (CRLM). However, resection of huge liver metastases from colon cancer has been seldom reported. PATIENT CONCERNS: A 58-year-old man presented with huge liver metastases from colon cancer. Laboratory tests revealed elevated tumor markers and a wild-type mutation in the K-RAS gene. A computed tomography scan demonstrated unresectable liver masses with a 16.5-cm maximum diameter and intrahepatic duct dilatation due to compression by the liver metastases. DIAGNOSIS: The patient was diagnosed with stage IV descending colon carcinoma with multiple huge hepatic metastases.

interventionsHe was administered 3 treatment courses, including 9 cycles of combined chemotherapy with mFOLFOX6 plus cetuximab (mFOLFOX6 + Cet), and the liver masses reduced. After a preoperative assessment by a multidisciplinary team when the 9 cycles of systemic chemotherapy had been completed, the patient underwent hepatectomy, followed 4 months later by a laparoscopic colectomy. We used a reverse strategy (liver-first) for the patient. OUTCOMES: In this case, liver-first treatment (systemic chemotherapy of mFOLFOX6 + Cet) was an effective treatment for unresectable CRLM. No postoperative complications occurred. The patient continued to receive postoperative chemotherapy (mFOLFOX6 + Cet) at the latest follow-up. During the 17 months of follow-up, tumor recurrence was un-noted. LESSONS: Treating colorectal cancer patients with huge hepatic metastases is possible, and surgeons should consider various treatment options in the management of these patients.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCetuximabChemotherapy, AdjuvantColonic NeoplasmsFluorouracilHumansLeucovorinLiver NeoplasmsMaleMiddle AgedOrganoplatinum CompoundsCetuximabFluorouracilLeucovorinOrganoplatinum Compounds

Identifiers

PMID31027071
PMCPMC6831392
OpenAlexW2941833476

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.